Bevacizumab with or without Radiation Therapy in Treating Patients with Recurrent Glioblastoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IITreatment18 and overRTOG 1205
NCI-2012-01732, NCT01730950

Trial Description

Summary

This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with glioblastoma that has returned after a period of improvement. Monoclonal antibodies, such as bevacizumab, may block tumor growth by targeting certain cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma.

Further Study Information

PRIMARY OBJECTIVES:

I. To establish an improvement in overall survival in recurrent glioblastoma multiforme (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.

SECONDARY OBJECTIVES:

I. To estimate and compare the rate of objective response in patients with measurable disease.

II. To estimate and compare the 6-month progression-free survival rate.

III. To estimate and compare progression-free survival.

IV. To estimate and compare the rate of treatment adverse events.

V. To estimate and compare the rate of >= grade 3 acute or delayed central nervous system (CNS) toxicity.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks.

ARM II: Patients receive bevacizumab as in Arm I and undergo radiation therapy using intensity-modulated radiation therapy (IMRT), 3-dimensional conformal radiation therapy (3D-CRT), or proton beam radiation therapy (RT) 5 days a week for 2 weeks.

In both arms, courses with bevacizumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 1 year, every 6 months for 1 year and then annually thereafter.

Eligibility Criteria

Inclusion Criteria:

Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative or intra-operative MRI scan (or CT scan for patients with non-compatible devices) must be performed prior to registration and should be within 96 hours post-surgery (although 24 hours would be optimum)

Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made

History/physical examination, including neurologic examination, within 14 days prior to registration

Prior history of standard dose CNS radiation of 60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower doses

Total bilirubin =< 2.0 mg/dL

Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement

Patients who have received prior treatment with non-standard radiation therapy (RT) dose and fractionation, interstitial brachytherapy, stereotactic radiosurgery, etc. are eligible

Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) within 21 days prior to registration

Karnofsky performance status >= 60 within 14 days prior to registration

Platelets >= 75,000 cells/mm^3

Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable)

Complete blood count (CBC)/differential obtained within 14 days prior to registration, with adequate bone marrow function

Absolute neutrophil count (ANC) >= 1,500 cells/mm^3

Serum glutamic oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal

Serum creatinine =< 1.8 mg/dL

Patient must be able to provide study-specific informed consent prior to study entry

Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within 7 days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on study treatment and for 6 months after

Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:

No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin

Patients must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:

New areas of tumor outside the original radiotherapy fields as determined by the investigator, or

Histologic confirmation of tumor through biopsy or resection, or

Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration

Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of 28 days prior to registration from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:

14 days from administration of vincristine

42 days from administration of nitrosoureas

21 days from administration of procarbazine

Urine protein:creatinine (UPC) ratio < 1.0 within 14 days prior to registration OR urine dipstick for proteinuria =< 2+ (patients discovered to have > 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is < 1.0 to be eligible; if the UPC ratio is >= 1.0 then the patients should undergo a 24-hour urine collection and must demonstrate =< 1g of protein in 24 hours to be eligible)

Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm

Patients having undergone recent resection of their glioblastoma (within 5 weeks prior to registration) must have recovered from the effects of surgery; for CNS related core or needle biopsies, a minimum of 7 days must have elapsed prior to registration

Exclusion Criteria:

Prior history of hypertensive crisis or hypertensive encephalopathy

Prior allergic reaction to the study drug (bevacizumab)

History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration

Gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration

Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)

More than three relapses

Infratentorial, or leptomeningeal evidence of recurrent disease

Recurrent or persistent tumor greater than 6 cm in maximum diameter

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) (including bevacizumab)

Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration

Transmural myocardial infarction within the last 6 months prior to registration

History of stroke or transient ischemic attack within 6 months prior to registration

Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function other than screening panel and coagulation parameters are not required for entry into this protocol

Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol specific requirements may also exclude immuno-compromised patients

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Christina I. Tsien, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

John B. Fiveash
Ph: 205-934-0309

John B. Fiveash
Principal Investigator

Mobile

University of South Alabama Mitchell Cancer Institute

John R. Russell
Ph: 877-904-4367
Email: pfrancisco@usouthal.edu

John R. Russell
Principal Investigator

Arizona
Phoenix

Saint Joseph's Hospital and Medical Center

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

California
Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Dublin

Epic Care-Dublin

James Henry Feusner
Ph: 510-450-7600

James Henry Feusner
Principal Investigator

Fresno

Fresno Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Michael Raymond Girvigian
Ph: 626-564-3455

Michael Raymond Girvigian
Principal Investigator

Oakland

Kaiser Permanente Oakland-Broadway

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Rancho Cardova

Kaiser Permanente-Rancho Cordova Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Roseville

The Permanente Medical Group-Roseville Radiation Oncology

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sacramento

South Sacramento Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Walnut Creek

John Muir Medical Center-Walnut Creek

Daniel Marc Chinn
Ph: 925-674-2580

Daniel Marc Chinn
Principal Investigator

Colorado
Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Memorial Hospital Colorado Springs

Brian Dennis Kavanagh
Ph: 720-848-0650

Brian Dennis Kavanagh
Principal Investigator

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Fort Collins

Poudre Valley Hospital

Brian Dennis Kavanagh
Ph: 720-848-0650

Brian Dennis Kavanagh
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
New Britain

The Hospital of Central Connecticut

Neal B. Goldberg
Ph: 860-224-5660

Neal B. Goldberg
Principal Investigator

Florida
Deerfield Beach

University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach

Fazilat Ishkanian
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Fazilat Ishkanian
Principal Investigator

Jacksonville

Baptist Cancer Institute

Mark Emerson Augspurger
Ph: 904-202-7051

Mark Emerson Augspurger
Principal Investigator

Miami

University of Miami Miller School of Medicine-Sylvester Cancer Center

Fazilat Ishkanian
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Fazilat Ishkanian
Principal Investigator

Georgia
Atlanta

Emory University Hospital Midtown

Ian Richard Crocker
Ph: 404-778-1868

Ian Richard Crocker
Principal Investigator

Emory University/Winship Cancer Institute

Ian Richard Crocker
Ph: 404-778-1868

Ian Richard Crocker
Principal Investigator

Northside Hospital

Sahar Esther Rosenbaum
Ph: 404-303-3355

Sahar Esther Rosenbaum
Principal Investigator

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Cumming

Northside Hospital-Forsyth

Sahar Esther Rosenbaum
Ph: 404-303-3355

Sahar Esther Rosenbaum
Principal Investigator

Hawaii
Honolulu

Queen's Medical Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Illinois
Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Northwestern University

Jeffrey Joel Raizer
Ph: 312-695-1301
Email: cancer@northwestern.edu

Jeffrey Joel Raizer
Principal Investigator

University of Chicago Comprehensive Cancer Center

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

University of Illinois

Matthew Koshy
Ph: 312-355-3046

Matthew Koshy
Principal Investigator

Joliet

Joliet Oncology-Hematology Associates Limited

Kulumani M. Sivarajan
Ph: 815-730-3098
Email: maureenc@jolietoncology.com

Kulumani M. Sivarajan
Principal Investigator

New Lennox

UC Comprehensive Cancer Center at Silver Cross

Steven J. Chmura
Ph: 773-834-7424

Steven J. Chmura
Principal Investigator

Warrenville

Cadence Cancer Center in Warrenville

Vinai Gondi
Ph: 630-352-5300

Vinai Gondi
Principal Investigator

Indiana
Indianapolis

IU Health Methodist Hospital

Mark Peter Langer
Ph: 317-274-2552

Mark Peter Langer
Principal Investigator

South Bend

Memorial Hospital of South Bend

David Alan Hornback
Ph: 800-284-7370

David Alan Hornback
Principal Investigator

Kentucky
Lexington

Baptist Health Lexington

Marta S. Hayne
Ph: 859-260-6425

Marta S. Hayne
Principal Investigator

University of Kentucky/Markey Cancer Center

John Lee Villano
Ph: 859-257-3379

John Lee Villano
Principal Investigator

Louisville

Norton Hospital Pavilion and Medical Campus

Aaron C. Spalding
Ph: 502-629-2500

Aaron C. Spalding
Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Shiao Y. Woo
Ph: 866-530-5516

Shiao Y. Woo
Principal Investigator

Maine
Scarborough

Maine Medical Center- Scarborough Campus

Ian Jared Bristol
Ph: 207-396-8090
Email: wrighd@mmc.org

Ian Jared Bristol
Principal Investigator

Maryland
Annapolis

Anne Arundel Medical Center

Peter Robert Graze
Ph: 443-481-1320
Email: kbodenhorn@aahs.org

Peter Robert Graze
Principal Investigator

Massachusetts
Boston

Brigham and Women's Hospital

Kevin Shawn Oh
Ph: 877-726-5130

Kevin Shawn Oh
Principal Investigator

Dana-Farber Cancer Institute

Kevin Shawn Oh
Ph: 877-726-5130

Kevin Shawn Oh
Principal Investigator

Massachusetts General Hospital Cancer Center

Kevin Shawn Oh
Ph: 877-726-5130

Kevin Shawn Oh
Principal Investigator

Tufts Medical Center

John Emory Mignano
Ph: 617-636-5000
Email: ContactUsCancerCenter@TuftsMedicalCenter.org

John Emory Mignano
Principal Investigator

Burlington

Lahey Hospital and Medical Center

Brian J. Scott
Ph: 781-744-8027

Brian J. Scott
Principal Investigator

Lowell

Lowell General Hospital

Matthew Strauss Katz
Ph: 978-788-7084
Email: ghincks@lowellgeneral.org

Matthew Strauss Katz
Principal Investigator

Springfield

Baystate Medical Center

Seth A. Kaufman
Ph: 413-794-9338

Seth A. Kaufman
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

University of Michigan Comprehensive Cancer Center

Christina I. Tsien
Ph: 734-936-4307
Email: ctsien@umich.edu

Christina I. Tsien
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Mississippi
Jackson

University of Mississippi Medical Center

Mark Daniel Anderson
Ph: 601-815-6700

Mark Daniel Anderson
Principal Investigator

Missouri
Rolla

Phelps County Regional Medical Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Saint Louis

Barnes-Jewish West County Hospital

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jiayi Huang
Principal Investigator

Washington University School of Medicine

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jiayi Huang
Principal Investigator

Springfield

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Omaha

Nebraska Methodist Hospital

Tien-Shew William Huang
Ph: 402-354-5144

Tien-Shew William Huang
Principal Investigator

Nevada
Henderson

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Las Vegas

Comprehensive Cancer Centers of Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Comprehensive Cancer Centers of Nevada-Summerlin

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Reno

Saint Mary's Regional Medical Center

Jonathan S. Tay
Ph: 775-770-7414

Jonathan S. Tay
Principal Investigator

New Jersey
Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

New Brunswick

UMDNJ - Robert Wood Johnson University Hospital

Sharad Goyal
Ph: 732-235-8675

Sharad Goyal
Principal Investigator

Voorhees

Virtua West Jersey Hospital Voorhees

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

New York
Bay Shore

Southside Hospital

Jonathan Petrus Sandberg Knisely
Ph: 516-562-3467

Jonathan Petrus Sandberg Knisely
Principal Investigator

Bronx

Montefiore Medical Center - Moses Campus

Mary Roberta Welch
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Mary Roberta Welch
Principal Investigator

New Hyde Park

North Shore-LIJ Health System/Center for Advanced Medicine

Jonathan Petrus Sandberg Knisely
Ph: 516-562-3467

Jonathan Petrus Sandberg Knisely
Principal Investigator

New York

Saint Luke's Roosevelt Hospital Center - Saint Luke's Division

Rahul R. Parikh
Ph: 212-824-7320
Email: jenny.figueroa@mssm.edu

Rahul R. Parikh
Principal Investigator

Rochester

University of Rochester

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

North Carolina
Gastonia

Gaston Memorial Hospital

Charles J. Meakin
Ph: 704-834-2932

Charles J. Meakin
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Akron

Akron General Medical Center

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Barberton

Summa Barberton Hospital

Charles Andrew Kunos
Ph: 330-375-6101

Charles Andrew Kunos
Principal Investigator

Cleveland

Case Western Reserve University

Simon Shek-Man Lo
Ph: 800-641-2422

Simon Shek-Man Lo
Principal Investigator

Columbus

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Kettering

Kettering Medical Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Oklahoma
Oklahoma City

Integris Southwest Medical Center

Gary L. Larson
Ph: 405-773-6613

Gary L. Larson
Principal Investigator

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Portland

Legacy Good Samaritan Hospital and Medical Center

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

Providence Portland Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Providence Saint Vincent Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Pennsylvania
Beaver

UPMC-Heritage Valley Health System Beaver

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

Bethlehem

Saint Luke's University Hospital-Bethlehem Campus

Nimisha Deb
Ph: 610-954-3582
Email: infolink@slhn.org

Nimisha Deb
Principal Investigator

Danville

Geisinger Medical Center

Thomas James Gergel
Ph: 570-271-5251

Thomas James Gergel
Principal Investigator

Greensburg

UPMC Cancer Centers - Arnold Palmer Pavilion

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

McKeesport

UPMC Cancer Center at UPMC McKeesport

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

Moon Township

UPMC-Coraopolis/Heritage Valley Radiation Oncology

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

Philadelphia

Aria Health-Torresdale Campus

Maria Werner-Wasik
Ph: 215-955-6084

Maria Werner-Wasik
Principal Investigator

Thomas Jefferson University Hospital

Maria Werner-Wasik
Ph: 215-955-6084

Maria Werner-Wasik
Principal Investigator

Pittsburgh

Allegheny General Hospital

Stephen Michael Karlovits
Ph: 877-284-2000

Stephen Michael Karlovits
Principal Investigator

UPMC-Passavant Hospital

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

UPMC-Saint Clair Hospital Cancer Center

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

UPMC-Saint Margaret

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

UPMC-Shadyside Hospital

John C. Flickinger
Ph: 412-647-2811

John C. Flickinger
Principal Investigator

West Reading

Reading Hospital

Albert Yuen
Ph: 610-988-9323

Albert Yuen
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Thomas James Gergel
Ph: 570-271-5251

Thomas James Gergel
Principal Investigator

South Carolina
Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg Medical Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J. Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Michael J. Swartz
Principal Investigator

Sioux Falls

Sanford USD Medical Center - Sioux Falls

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Tennessee
Knoxville

The Center for Biomedical Research

Marcio Augusto Fagundes
Ph: 865-244-3209

Marcio Augusto Fagundes
Principal Investigator

Thompson Cancer Survival Center

Daniel D. Scaperoth
Ph: 865-541-1812

Daniel D. Scaperoth
Principal Investigator

Maryville

Blount Memorial Hospital

Daniel D. Scaperoth
Ph: 865-541-1812

Daniel D. Scaperoth
Principal Investigator

Texas
Austin

University Medical Center Brackenridge

Mateo Ziu
Ph: 512-324-7991

Mateo Ziu
Principal Investigator

Galveston

University of Texas Medical Branch

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

League City

UTMB Cancer Center at Victory Lakes

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

Lubbock

Covenant Medical Center-Lakeside

Paul J. Anderson
Ph: 806-725-8000
Email: jaccresearch@covhs.org

Paul J. Anderson
Principal Investigator

Vermont
Burlington

University of Vermont Medical Center

Steven Patrick Emmons
Ph: 802-656-8990

Steven Patrick Emmons
Principal Investigator

Virginia
Falls Church

Inova Fairfax Hospital

Samir Padmasen Kanani
Ph: 703-208-6650

Samir Padmasen Kanani
Principal Investigator

Richmond

Virginia Commonwealth University/Massey Cancer Center

Douglas William Arthur
Ph: 804-628-1939

Douglas William Arthur
Principal Investigator

Washington
Kennewick

Tri-Cities Cancer Center

George E. Laramore
Ph: 206-616-8289

George E. Laramore
Principal Investigator

Longview

Saint John Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Mount Vernon

Skagit Valley Hospital Regional Cancer Care Center

George E. Laramore
Ph: 206-616-8289

George E. Laramore
Principal Investigator

Seattle

University of Washington Medical Center

George E. Laramore
Ph: 206-616-8289

George E. Laramore
Principal Investigator

Virginia Mason Medical Center

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Yakima

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Sean F. Cleary
Ph: 877-902-3324

Sean F. Cleary
Principal Investigator

Wisconsin
Green Bay

Saint Mary's Hospital

Gregory M. Cooley
Ph: 920-433-8889

Gregory M. Cooley
Principal Investigator

Saint Vincent Hospital

Gregory M. Cooley
Ph: 920-433-8889

Gregory M. Cooley
Principal Investigator

Marinette

Bay Area Medical Center

Gregory M. Cooley
Ph: 920-433-8889

Gregory M. Cooley
Principal Investigator

Mukwonago

D N Greenwald Center

Wingate F. Clapper
Ph: 262-928-7632

Wingate F. Clapper
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Wingate F. Clapper
Ph: 262-928-7632

Wingate F. Clapper
Principal Investigator

Sturgeon Bay

Door County Cancer Center

Gregory M. Cooley
Ph: 920-433-8889

Gregory M. Cooley
Principal Investigator

Waukesha

Waukesha Memorial Hospital

Wingate F. Clapper
Ph: 262-928-7632

Wingate F. Clapper
Principal Investigator

Canada

Saskatchewan
Regina

Allan Blair Cancer Centre

Tak Hing Patricia Tai
Ph: 306-766-2213

Tak Hing Patricia Tai
Principal Investigator

Israel

Tel Aviv

Tel Aviv Sourasky Medical Center

Felix Bokstein
Ph: 011-972-3-6974761
Email: mop@tasmc.health.gov.il

Felix Bokstein
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01730950

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.